CoChat

Statin use and the risk of developing diabetes: a network meta‐analysis

Thakker, Divyesh, Nair, Sunita, Pagada, Amit, Jamdade, Vinayak, Malik, Anuradha · 2016 · Pharmacoepidemiology and Drug Safety
Cited by 144

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Purpose: Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta‐analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices. Methods: We identified studies relevant to our NMA by performing study searches in databases like Embase, Cochrane, and PubMed, published between August 2010 and June 2014. Pre‐2010 studies were identified from bibliography of previously published meta‐analyses. Unpublished study data were found from clinicaltrial.gov. Data synthesis was performed by pairwise meta‐analysis and NMA within a Frequentist framework. Results: Twenty nine trials in which 1 63 039 participants had been randomized were included in this review; among these 1 41 863 were non‐diabetic patients. The direct meta‐analysis showed that statins, as a class, significantly increased the likelihood of developing diabetes by 12% (pooled OR 1.12; 95%CI 1.05–1.21; I 2 36%;p = 0.002; 18 RCTs). In the NMA, atorvastatin 80 mg was associated with a highest risk of diabetes, with OR of 1.34 (95%CI 1.14–1.57) followed by rosuvastatin (OR: 1.17; 95%CI: 1.02–1.35). The ORs (95%CIs) for simvastatin 80 mg, simvastatin, atorvastatin, pravastatin, lovastatin and pitavastatin were 1.21 (0.99–1.49), 1.13 (0.99–1.29), 1.13 (0.94–1.34), 1.04 (0.93–1.16), 0.98 (0.69–1.38) and 0.74 (0.31–1.77), respectively. High‐dose atorvastatin increased the odds of developing diabetes even when compared with pravastatin, simvastatin and low‐dose atorvastatin in the NMA. Conclusions: Based on the results, statins, as a class, increased the risk of diabetes significantly in the pairwise meta‐analysis. Overall, there appears to be a small increased risk of incident diabetes, particularly with more intensive statin therapy, although more data would be valuable to increase the robustness of this interpretation, given that the lower confidence intervals of our study analyses are close to, or just crossing one. Copyright © 2016 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pds.4020

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 144

Metadata

Authors
Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A.
Venue
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Published
2016-06-09
Volume
25
Issue
10
Pages
1131-1149
ISSN
  • 1053-8569 (ISSN-L)
  • 1099-1557
OpenAlex
W2414525849
Cited by
144
References
22
FWCI
14.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statin use and the risk of developing diabetes: a network meta‐analysis. https://app.cochat.ai/papers/10.1002/pds.4020
The paper
Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A. (2016). Statin use and the risk of developing diabetes: a network meta‐analysis. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.4020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.